Exelixis, Inc. (NASDAQ: EXEL)

Exelixis, Inc. is an oncology company focused on discovering, developing, and commercializing next-generation medicines for the treatment of cancer. The company's core business involves advancing small molecule and biotherapeutic candidates through preclinical and clinical development, with an emphasis on tyrosine kinase inhibitors and antibody-drug conjugates. Exelixis generates revenue primarily from the sale of its marketed products and royalties earned through collaboration agreements.

Revenue is generated mainly through net product sales of CABOMETYX® and COMETRIQ®, which account for the majority of the company's income. Additional revenue comes from royalties on net sales of cabozantinib products outside the United States, earned under collaboration agreements with Ipsen and Takeda. The company serves healthcare providers, patients, and healthcare systems globally, with a focus on oncologists and specialty treatment centers.

The company operates through the following segments: Oncology Therapeutics and Collaborative Development.

• Oncology Therapeutics: This segment encompasses the discovery, development, and commercialization of Exelixis' proprietary oncology products, including small molecules and biotherapeutics. Key marketed products include CABOMETYX® (cabozantinib) tablets and COMETRIQ® (cabozantinib) capsules for various cancer indications. The segment also includes pipeline candidates such as zanzalintinib, XL309, XB010, XB628, and XB371, each targeting specific kinases or biological pathways in solid tumors.

• Collaborative Development: This segment involves strategic partnerships with third-party companies to advance the development and commercialization of Exelixis' product candidates. Collaborations include agreements with Ipsen and Takeda for the global commercialization of cabozantinib outside the U. S. and Japan, respectively. Additional partnerships exist with Roche, BMS, Merck, Catalent, Invenra, Adagene, Sairopa, and Insilico for the co-development of antibody-drug conjugates, bispecific antibodies, and small molecule inhibitors.

Exelixis holds a strong position in the oncology therapeutics market, particularly as a leader in tyrosine kinase inhibitor development for renal cell carcinoma and other hard-to-treat cancers. The company competes with major pharmaceutical firms such as Bristol-Myers Squibb, Merck & Co., Eisai, and Novartis, but differentiates itself through its focused pipeline, clinical trial data, and strategic collaborations that enhance its development capabilities and market reach.

Exelixis serves patients, healthcare providers, hospitals, and specialty oncology clinics worldwide. Specific customer names are not disclosed in the filing, but the company's products are distributed through wholesale and specialty pharmacy channels to end-users treating advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, pancreatic and extra-pancreatic neuroendocrine tumors, and medullary thyroid cancer.